Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96N76

UPID:
HUTU_HUMAN

ALTERNATIVE NAMES:
Imidazolonepropionate hydrolase

ALTERNATIVE UPACC:
Q96N76; E9PE13; Q14C64; Q68CJ7

BACKGROUND:
The enzyme Urocanate hydratase, known alternatively as Imidazolonepropionate hydrolase, is pivotal in breaking down histidine, an essential amino acid. Its activity ensures the smooth progression of histidine to imidazolone-5-propionate, integral for maintaining metabolic balance.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Urocanate hydratase could open doors to potential therapeutic strategies. Its direct involvement in Urocanase deficiency, characterized by severe neurological manifestations, highlights its potential as a therapeutic target. Developing inhibitors or activators could offer relief to affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.